APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

Cancer Management and Research

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2uWwrDD
via IFTTT